CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia-related changes in adults in 2017 (US; updated to patients aged & GE;1 year in 2021) and 2018 (EU/UK) based on improved survival and remission and comparable safety versus 7 + 3 chemotherapy in a randomized trial in older adults. Real-world studies have since evaluated CPX-351 in routine practice across several countries and addressed important data gaps (e.g., use in younger adults, measurable residual disease negativity, outcomes by mutation). This review discusses realworld studies of CPX-351 as AML treatment, with the aim of helping prescribers make informed treatment decisions.
Real-world experience with CPX-351 in high-risk acute myeloid leukemia
Lemoli, Roberto M;
2023-01-01
Abstract
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia-related changes in adults in 2017 (US; updated to patients aged & GE;1 year in 2021) and 2018 (EU/UK) based on improved survival and remission and comparable safety versus 7 + 3 chemotherapy in a randomized trial in older adults. Real-world studies have since evaluated CPX-351 in routine practice across several countries and addressed important data gaps (e.g., use in younger adults, measurable residual disease negativity, outcomes by mutation). This review discusses realworld studies of CPX-351 as AML treatment, with the aim of helping prescribers make informed treatment decisions.
| File | Dimensione | Formato | |
|---|---|---|---|
|
CPX-review 2023.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
621.18 kB
Formato
Adobe PDF
|
621.18 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
